ATE274056T1 - Kombination pdgf, kgf, igf und igfbp zur wundheilung - Google Patents

Kombination pdgf, kgf, igf und igfbp zur wundheilung

Info

Publication number
ATE274056T1
ATE274056T1 AT96933952T AT96933952T ATE274056T1 AT E274056 T1 ATE274056 T1 AT E274056T1 AT 96933952 T AT96933952 T AT 96933952T AT 96933952 T AT96933952 T AT 96933952T AT E274056 T1 ATE274056 T1 AT E274056T1
Authority
AT
Austria
Prior art keywords
kgf
igf
igfbp
pdgf
wound healing
Prior art date
Application number
AT96933952T
Other languages
English (en)
Inventor
Lewis T Williams
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE274056T1 publication Critical patent/ATE274056T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1754—Insulin-like growth factor binding proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0028—Polypeptides; Proteins; Degradation products thereof
    • A61L26/0047—Specific proteins or polypeptides not covered by groups A61L26/0033 - A61L26/0042
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Materials Engineering (AREA)
  • Toxicology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96933952T 1995-10-11 1996-09-27 Kombination pdgf, kgf, igf und igfbp zur wundheilung ATE274056T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US507595P 1995-10-11 1995-10-11
US2154096P 1996-07-11 1996-07-11
US71974296A 1996-09-25 1996-09-25
PCT/US1996/015623 WO1997013857A1 (en) 1995-10-11 1996-09-27 Combination pdgf, kgf, igf and igfbp for wound healing

Publications (1)

Publication Number Publication Date
ATE274056T1 true ATE274056T1 (de) 2004-09-15

Family

ID=27357798

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96933952T ATE274056T1 (de) 1995-10-11 1996-09-27 Kombination pdgf, kgf, igf und igfbp zur wundheilung

Country Status (10)

Country Link
US (2) US6903078B1 (de)
EP (2) EP0871730B1 (de)
JP (2) JPH11513405A (de)
AT (1) ATE274056T1 (de)
AU (1) AU7248896A (de)
DE (2) DE69637332T2 (de)
DK (1) DK1486565T3 (de)
ES (2) ES2293137T3 (de)
PT (2) PT1486565E (de)
WO (1) WO1997013857A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7248896A (en) 1995-10-11 1997-04-30 Chiron Corporation Combination pdgf, kgf, igf and igfbp for wound healing
EP0941110B1 (de) * 1996-10-15 2004-02-18 Amgen Inc., Verwendung von keratinocyten-wachstumsfaktor-2
US6743422B1 (en) 1996-10-15 2004-06-01 Amgen, Inc. Keratinocyte growth factor-2 products
EP1452205B1 (de) * 1996-10-15 2007-11-28 Amgen Inc. Verwendung von keratinocyte growth factor-2
DE69830320T2 (de) 1997-03-07 2006-02-02 The Wistar Institute Of Anatomy And Biology Verwendung von Adenoviralen Vektoren, die PDGF oder VEGF exprimieren, ZUR HEILUNG VON GEWEBSDEFEKTEN UND ZUR INDUZIERUNG DER HYPERVASKULITÄT IN SÄUGERGEWEBEN
AU2002331669A1 (en) 2001-08-23 2003-03-10 The Wistar Institute Of Anatomy And Biology An organotypic intestinal culture and methods of use thereof
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
CA2475388A1 (en) * 2002-02-14 2003-08-21 William J. Rutter Chimeric molecules for cleavage in a treated host
US20050224082A1 (en) * 2004-04-05 2005-10-13 Johnson Arthur A Method for forming occlusive barrier over ear canal and kit for providing same
US7799754B2 (en) 2004-10-14 2010-09-21 Biomimetic Therapeutics, Inc. Compositions and methods for treating bone
US7473678B2 (en) 2004-10-14 2009-01-06 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods of use thereof
US20070004036A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for keratinocyte culture
US20070003541A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for therapeutics
US20070128685A1 (en) * 2005-07-01 2007-06-07 Rodolfo Faudoa Methods and compositions for cell culture
EP2431060B1 (de) 2005-11-17 2020-04-08 BioMimetic Therapeutics, LLC Kiefer- und Gesichtsknochenerweiterung mithilfe von RHPDGF-BB und einer biokompatiblen Matrix
GB0611405D0 (en) * 2006-06-09 2006-07-19 Univ Belfast FKBP-L: A novel inhibitor of angiogenesis
ES2664229T3 (es) 2006-06-30 2018-04-18 Biomimetic Therapeutics, Llc Composiciones y métodos de biomatriz-PDGF para el tratamiento de lesiones del manguito rotador
US9161967B2 (en) 2006-06-30 2015-10-20 Biomimetic Therapeutics, Llc Compositions and methods for treating the vertebral column
US20080119433A1 (en) * 2006-07-06 2008-05-22 Aaron Thomas Tabor Compositions and Methods for Genetic Modification of Cells Having Cosmetic Function to Enhance Cosmetic Appearance
JP5552315B2 (ja) 2006-11-03 2014-07-16 バイオミメティック セラピューティクス， エルエルシー アースロデティック術のための組成物および方法
RU2542471C2 (ru) * 2006-11-15 2015-02-20 Коуда Терапьютикс, Инк. Улучшенные способы и композиции для заживления ран
US20080195476A1 (en) * 2007-02-09 2008-08-14 Marchese Michael A Abandonment remarketing system
EP2234656A2 (de) 2007-12-21 2010-10-06 Coda Therapeutics, Inc. Verbesserte medizinische vorrichtungen
EP2252690A2 (de) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Verwendung von anti-connexin-43-polynukleotiden zur behandlung abnormaler oder übermässiger narben
AU2008343840A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides, peptides or antibodies for the treatment of orthopedic conditions
WO2009100454A1 (en) * 2008-02-07 2009-08-13 Biomimetic Therapeutics, Inc. Compositions and methods for distraction osteogenesis
KR101021197B1 (ko) * 2008-04-11 2011-03-11 (주)케어젠 성장인자―미미킹 펩타이드 및 그의 용도
NZ602861A (en) 2008-09-09 2014-03-28 Biomimetic Therapeutics Llc Platelet-derived growth factor compositions and methods for the treatment of tendon and ligament injuries
JP2012519556A (ja) * 2009-03-05 2012-08-30 バイオミメティック セラピューティクス， インコーポレイテッド 骨軟骨欠損を治療するための血小板由来増殖因子組成物および方法
BR112012000865A2 (pt) 2009-07-17 2019-09-24 T Tabor Aaron "composição e método para a modificação genética cosmética de células substancialmente intactas"
CA2790403C (en) 2010-02-22 2019-08-27 Biomimetic Therapeutics, Inc. Platelet-derived growth factor compositions and methods for the treatment of tendinopathies
US10279007B2 (en) 2010-11-15 2019-05-07 Oxygenetix Institute, Inc. Topical treatment method for healing wounds, disinfecting, covering and concealing the wound until healing occurs
US20160250298A1 (en) 2013-11-01 2016-09-01 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
WO2016029191A2 (en) 2014-08-22 2016-02-25 Auckland Uniservices Limited Channel modulators
CA2962954A1 (en) 2014-10-14 2016-04-21 Samuel Lynch Compositions for treating wounds
CN110590930B (zh) * 2018-06-13 2023-03-31 四川好医生攀西药业有限责任公司 美洲大蠊生长因子pdgf在制备损伤修复药物中的应用
US12667586B2 (en) 2023-03-07 2026-06-30 Glaukos Corporation Treatments for ocular surface disorders

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE95236T1 (de) 1983-04-25 1993-10-15 Chiron Corp Hybrid-dns-synthesis von reifen insulinaehnlichen wachstumsfaktoren.
US4766073A (en) * 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US4801542A (en) * 1984-10-12 1989-01-31 Zymogenetics, Inc. Expression of biologically active PDGF analogs in eucaryotic cells
US5187263A (en) 1984-10-12 1993-02-16 Zymogenetics, Inc. Expression of biologically active PDGE analogs in eucaryotic cells
ATE131532T1 (de) * 1986-08-13 1995-12-15 Zymogenetics Inc Expression von biologisch-aktiven pdgf-analogen in eukaryotischen zellen
US5019559A (en) 1986-11-14 1991-05-28 President And Fellows Of Harvard College Wound healing using PDGF and IGF-II
CA1322714C (en) 1986-11-14 1993-10-05 Harry N. Antoniades Wound healing and bone regeneration
KR960005708B1 (ko) * 1986-11-14 1996-05-01 인스티튜트 오브 몰레큘러 바이올로지, 인코오포레이티드 외상 치료 및 뼈 재생용 조성물
US4885163A (en) 1987-02-24 1989-12-05 Eli Lilly And Company Topical use of IGF-II for wound healing
US5422120A (en) * 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
DK0555205T3 (da) 1989-01-31 2001-03-05 Jeffrey S Rubin DNA, der koder for en væstfaktor, som er specifik for epitelceller
US5035887A (en) 1989-09-07 1991-07-30 Institute Of Moelcular Biology, Inc. Wound healing composition of IL-1 and PDGF or IGF-1
US5149792A (en) * 1989-12-19 1992-09-22 Amgen Inc. Platelet-derived growth factor B chain analogs
JPH04224522A (ja) * 1990-04-27 1992-08-13 Merck & Co Inc 繊維芽細胞増殖因子含有組成物による禿頭症の治療又は予防方法
WO1992001716A1 (en) * 1990-07-23 1992-02-06 Zymogenetics, Inc. Protease resistant pdgf and methods of use
US5212074A (en) 1990-08-28 1993-05-18 Chiron Corporation Genetic material encoding new insulin-like growth factor binding protein igfbp-6
PT98805B (pt) 1990-08-28 1999-01-29 Chiron Corp Processo de preparacao de uma nova proteina de ligacao ao factor de crescimento semelhante a insulina (igfbp-4)
CA2090705A1 (en) 1990-08-28 1992-03-01 Michael C. Kiefer Genetic material encoding igfbp-5
WO1992012243A1 (en) 1991-01-08 1992-07-23 Chiron Corporation New insulin-like growth factor binding protein (igfbp-6)
JPH05506673A (ja) * 1991-02-22 1993-09-30 アムジエン・インコーポレーテツド 迅速な創傷の治癒を促進するためのｇｍ―ｃｓｆ及びｇ―ｃｓｆの使用
CZ283601B6 (cs) 1991-04-19 1998-05-13 Subburaman Mohan Inzulinu podobný růstový faktor vázající protein odvozený z lidské kosti
HUT67319A (en) 1991-08-30 1995-03-28 Life Medical Sciences Inc Compositions for treating wounds
IL105529A0 (en) 1992-05-01 1993-08-18 Amgen Inc Collagen-containing sponges as drug delivery for proteins
ES2174852T3 (es) * 1992-08-26 2002-11-16 Celtrix Pharma Metodo para el tratamiento sistemico de estados catabolicos y lesiones sistemicas de tejidos.
US5407913A (en) 1992-12-03 1995-04-18 Celtrix Pharmaceuticals, Inc. Method and composition for systemic treatment of tissue injury
AU6093794A (en) * 1993-01-29 1994-08-15 Synergen, Inc. Wound healing composition
HU220641B1 (hu) * 1993-03-26 2002-03-28 Amgen Inc. Keratinocita növekedési faktor alkalmazása
US5750365A (en) * 1993-05-28 1998-05-12 The Ohio State University Research Foundation Isolated nucleic acid encoding a newt acidic fibroblast growth factor (AFGF)
NZ266622A (en) 1993-06-29 1997-10-24 Chiron Corp Keratinocyte growth factor fragment (kgf) with at least a 2-fold increase in mitogenic activity compared to a full length kgf; dna molecules, expression vectors, host cells, and conjugates
US5624893A (en) 1993-10-14 1997-04-29 Alcon Laboratories, Inc. Pharmaceutical compositions and methods of treatment of the cornea following laser irradiation
US5962427A (en) * 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
AU7248896A (en) 1995-10-11 1997-04-30 Chiron Corporation Combination pdgf, kgf, igf and igfbp for wound healing

Also Published As

Publication number Publication date
PT871730E (pt) 2004-11-30
JPH11513405A (ja) 1999-11-16
DE69633194T2 (de) 2005-09-08
EP1486565A1 (de) 2004-12-15
HK1067382A1 (en) 2005-04-08
US6903078B1 (en) 2005-06-07
ES2293137T3 (es) 2008-03-16
EP0871730B1 (de) 2004-08-18
DE69633194D1 (de) 2004-10-21
AU7248896A (en) 1997-04-30
US20050250695A1 (en) 2005-11-10
PT1486565E (pt) 2008-02-28
DK1486565T3 (da) 2008-03-10
EP1486565B1 (de) 2007-11-21
DE69637332T2 (de) 2008-10-09
EP0871730A1 (de) 1998-10-21
WO1997013857A1 (en) 1997-04-17
JP2007182461A (ja) 2007-07-19
DE69637332D1 (de) 2008-01-03
ES2224178T3 (es) 2005-03-01

Similar Documents

Publication Publication Date Title
DE69633194D1 (de) Kombination pdgf, kgf, igf und igfbp zur wundheilung
NL300433I1 (en) Methods and compositions for the treatment of glomerulonephritis
ID21924A (id) Olanzapin dihidrat d
DK1489082T3 (da) Mellemprodukter
AU4187297A (en) Process and apparatus for coating surgical sutures
DK0871473T3 (da) Anvendelse af IL-10 til sårheling med reduceret ardannelse
FI971568A0 (fi) Menetelmä resistenttien kasvainten hoitamiseksi
DE4397203T1 (de) Helligkeitssteuersystem für eine zahnärztliche Handstückbeleuchtung
DE69535453D1 (de) Zusammensetzungen zur Verbesserung der Immunantwort
BR9813996A (pt) 2-arilbenzo[b]tiofenos úteis para o tratamento de sìndrome da privação de estrogênio
DK1291018T3 (da) Phosphonatananaloger til mannose-6phosphat og deres anvendelse i behandlingen af sår og fibrotiske lidelser
AU1278600A (en) Novel therapeutic application of nicergoline
GB9516967D0 (en) Pharmaceutical composition
AU1506692A (en) Pharmaceutical compositions
DE59711240D1 (de) Verwendung von flupirtin zur therapie und prophylaxe von myokardinfarkt, schockniere und schocklunge
MY140504A (en) Statin-mmp inhibitor combinations
PT661058E (pt) Utilizacao de antagonistas da bradiquinina para o tratamento de doencas virais
ATE305795T1 (de) Verwendung von wachstumshormon und analoga davon für die behandlung von säugern mit familiärer hypercholesterolämie
AU1278700A (en) Novel therapeutic use of 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergoline

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0871730

Country of ref document: EP